A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development

Antonio Jimeno, Georg Feldmann, Ana Suárez-Gauthier, Zeshaan Rasheed, Anna Solomon, Gang Ming Zou, Belen Rubio-Viqueira, Elena García-García, Fernando López-Ríos, William Matsui, Anirban Maitra, Manuel Hidalgo

Research output: Contribution to journalArticle

Abstract

There is an enormous gap between the antiproliferative and in vivo antitumor efficacy of gemcitabine in cell line-based models and its clinical efficacy. This may be due to insensitiveness of the precursor, cancer stem cell (CSC) compartment to cytotoxic agents. The hedgehog pathway is associated with CSC signaling and control. We used a direct xenograft model of pancreatic cancer and a two-stage approach was used to test the hypotheses that targeting CSC could increase the efficacy of gemcitabine. Tumors from a gemcitabine-sensitive xenograft were treated with gemcitabine first, and randomized, after tumor regression to continuing treatment with gemcita-bine, a hedgehog inhibitor alone or in combination with gemcitabine. We tested markers described as associated with CSC such as CD24, CD44, ALDH, nestin, and the hedgehog pathway. After induction with gemcitabine, treated tumor showed an enrichment in CSC markers such as ALDH and CD24. Subsequently, a release from gemcitabine prompted a repopulation of proliferating cells and a decrease in such markers to equilibrate from pretreatment levels. Combined treatment with gemcita-bine and cyclopamine induced tumor regression and decrease in CSC markers and hedgehog signaling. Cyto-plasmic CD24 and ALDH were inversely and strongly associated with growth and were expressed in a minority of cells that we propose constitute the CSC compartment. Hedgehog inhibitors as part of a dual compartment therapeutic approach were able to further reduce tumor growth and decreased both static and dynamic markers of CSC. Direct tumor xenografts are a valid platform to test multicompartment therapeutic approaches in pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)310-314
Number of pages5
JournalMolecular Cancer Therapeutics
Volume8
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

gemcitabine
Neoplastic Stem Cells
Pancreatic Neoplasms
Heterografts
Neoplasms
Therapeutics
Nestin
Cytotoxins
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jimeno, A., Feldmann, G., Suárez-Gauthier, A., Rasheed, Z., Solomon, A., Zou, G. M., ... Hidalgo, M. (2009). A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Molecular Cancer Therapeutics, 8(2), 310-314. https://doi.org/10.1158/1535-7163.MCT-08-0924

A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. / Jimeno, Antonio; Feldmann, Georg; Suárez-Gauthier, Ana; Rasheed, Zeshaan; Solomon, Anna; Zou, Gang Ming; Rubio-Viqueira, Belen; García-García, Elena; López-Ríos, Fernando; Matsui, William; Maitra, Anirban; Hidalgo, Manuel.

In: Molecular Cancer Therapeutics, Vol. 8, No. 2, 01.02.2009, p. 310-314.

Research output: Contribution to journalArticle

Jimeno, A, Feldmann, G, Suárez-Gauthier, A, Rasheed, Z, Solomon, A, Zou, GM, Rubio-Viqueira, B, García-García, E, López-Ríos, F, Matsui, W, Maitra, A & Hidalgo, M 2009, 'A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development', Molecular Cancer Therapeutics, vol. 8, no. 2, pp. 310-314. https://doi.org/10.1158/1535-7163.MCT-08-0924
Jimeno, Antonio ; Feldmann, Georg ; Suárez-Gauthier, Ana ; Rasheed, Zeshaan ; Solomon, Anna ; Zou, Gang Ming ; Rubio-Viqueira, Belen ; García-García, Elena ; López-Ríos, Fernando ; Matsui, William ; Maitra, Anirban ; Hidalgo, Manuel. / A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. In: Molecular Cancer Therapeutics. 2009 ; Vol. 8, No. 2. pp. 310-314.
@article{5b67a637e3124ecaa912488d43f54fb3,
title = "A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development",
abstract = "There is an enormous gap between the antiproliferative and in vivo antitumor efficacy of gemcitabine in cell line-based models and its clinical efficacy. This may be due to insensitiveness of the precursor, cancer stem cell (CSC) compartment to cytotoxic agents. The hedgehog pathway is associated with CSC signaling and control. We used a direct xenograft model of pancreatic cancer and a two-stage approach was used to test the hypotheses that targeting CSC could increase the efficacy of gemcitabine. Tumors from a gemcitabine-sensitive xenograft were treated with gemcitabine first, and randomized, after tumor regression to continuing treatment with gemcita-bine, a hedgehog inhibitor alone or in combination with gemcitabine. We tested markers described as associated with CSC such as CD24, CD44, ALDH, nestin, and the hedgehog pathway. After induction with gemcitabine, treated tumor showed an enrichment in CSC markers such as ALDH and CD24. Subsequently, a release from gemcitabine prompted a repopulation of proliferating cells and a decrease in such markers to equilibrate from pretreatment levels. Combined treatment with gemcita-bine and cyclopamine induced tumor regression and decrease in CSC markers and hedgehog signaling. Cyto-plasmic CD24 and ALDH were inversely and strongly associated with growth and were expressed in a minority of cells that we propose constitute the CSC compartment. Hedgehog inhibitors as part of a dual compartment therapeutic approach were able to further reduce tumor growth and decreased both static and dynamic markers of CSC. Direct tumor xenografts are a valid platform to test multicompartment therapeutic approaches in pancreatic cancer.",
author = "Antonio Jimeno and Georg Feldmann and Ana Su{\'a}rez-Gauthier and Zeshaan Rasheed and Anna Solomon and Zou, {Gang Ming} and Belen Rubio-Viqueira and Elena Garc{\'i}a-Garc{\'i}a and Fernando L{\'o}pez-R{\'i}os and William Matsui and Anirban Maitra and Manuel Hidalgo",
year = "2009",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-08-0924",
language = "English (US)",
volume = "8",
pages = "310--314",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development

AU - Jimeno, Antonio

AU - Feldmann, Georg

AU - Suárez-Gauthier, Ana

AU - Rasheed, Zeshaan

AU - Solomon, Anna

AU - Zou, Gang Ming

AU - Rubio-Viqueira, Belen

AU - García-García, Elena

AU - López-Ríos, Fernando

AU - Matsui, William

AU - Maitra, Anirban

AU - Hidalgo, Manuel

PY - 2009/2/1

Y1 - 2009/2/1

N2 - There is an enormous gap between the antiproliferative and in vivo antitumor efficacy of gemcitabine in cell line-based models and its clinical efficacy. This may be due to insensitiveness of the precursor, cancer stem cell (CSC) compartment to cytotoxic agents. The hedgehog pathway is associated with CSC signaling and control. We used a direct xenograft model of pancreatic cancer and a two-stage approach was used to test the hypotheses that targeting CSC could increase the efficacy of gemcitabine. Tumors from a gemcitabine-sensitive xenograft were treated with gemcitabine first, and randomized, after tumor regression to continuing treatment with gemcita-bine, a hedgehog inhibitor alone or in combination with gemcitabine. We tested markers described as associated with CSC such as CD24, CD44, ALDH, nestin, and the hedgehog pathway. After induction with gemcitabine, treated tumor showed an enrichment in CSC markers such as ALDH and CD24. Subsequently, a release from gemcitabine prompted a repopulation of proliferating cells and a decrease in such markers to equilibrate from pretreatment levels. Combined treatment with gemcita-bine and cyclopamine induced tumor regression and decrease in CSC markers and hedgehog signaling. Cyto-plasmic CD24 and ALDH were inversely and strongly associated with growth and were expressed in a minority of cells that we propose constitute the CSC compartment. Hedgehog inhibitors as part of a dual compartment therapeutic approach were able to further reduce tumor growth and decreased both static and dynamic markers of CSC. Direct tumor xenografts are a valid platform to test multicompartment therapeutic approaches in pancreatic cancer.

AB - There is an enormous gap between the antiproliferative and in vivo antitumor efficacy of gemcitabine in cell line-based models and its clinical efficacy. This may be due to insensitiveness of the precursor, cancer stem cell (CSC) compartment to cytotoxic agents. The hedgehog pathway is associated with CSC signaling and control. We used a direct xenograft model of pancreatic cancer and a two-stage approach was used to test the hypotheses that targeting CSC could increase the efficacy of gemcitabine. Tumors from a gemcitabine-sensitive xenograft were treated with gemcitabine first, and randomized, after tumor regression to continuing treatment with gemcita-bine, a hedgehog inhibitor alone or in combination with gemcitabine. We tested markers described as associated with CSC such as CD24, CD44, ALDH, nestin, and the hedgehog pathway. After induction with gemcitabine, treated tumor showed an enrichment in CSC markers such as ALDH and CD24. Subsequently, a release from gemcitabine prompted a repopulation of proliferating cells and a decrease in such markers to equilibrate from pretreatment levels. Combined treatment with gemcita-bine and cyclopamine induced tumor regression and decrease in CSC markers and hedgehog signaling. Cyto-plasmic CD24 and ALDH were inversely and strongly associated with growth and were expressed in a minority of cells that we propose constitute the CSC compartment. Hedgehog inhibitors as part of a dual compartment therapeutic approach were able to further reduce tumor growth and decreased both static and dynamic markers of CSC. Direct tumor xenografts are a valid platform to test multicompartment therapeutic approaches in pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=60849118097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849118097&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-08-0924

DO - 10.1158/1535-7163.MCT-08-0924

M3 - Article

C2 - 19174553

AN - SCOPUS:60849118097

VL - 8

SP - 310

EP - 314

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -